Over-the-counter (OTC) medications are among the most widely consumed pharmaceutical products globally. From antihistamines to antacids, their accessibility and affordability make them a critical component of public health. However, rising concerns about the presence of nitrosamine impurities in these products have triggered a wave of regulatory scrutiny. Agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada now mandate stringent testing and risk assessment protocols to ensure drug safety.
This comprehensive guide explores the regulatory framework, scientific basis, and practical steps that OTC drug manufacturers must follow to comply with nitrosamine analysis requirements, particularly in Canada and the United States. As the regulatory landscape evolves, this guide will help manufacturers maintain compliance while ensuring consumer safety.
What Are Nitrosamines and Why Are They Concerning?
Nitrosamines are chemical compounds classified as probable human carcinogens. They can form during the manufacturing, packaging, or storage of pharmaceuticals due to reactions between nitrites and amines under specific conditions. Examples of nitrosamines include NDMA (N-Nitrosodimethylamine) and NDEA (N-Nitrosodiethylamine).
These impurities have been detected in a variety of drug products, including OTC medications such as ranitidine and nizatidine, leading to recalls and public health alerts (Dunn et al., 2020).
Learn more about nitrosamine impurities in pharmaceuticals
Regulatory Landscape: Canada and the United States
1. FDA Guidelines
The FDA has issued several guidance documents focused on nitrosamine impurity control:
- Control of Nitrosamine Impurities in Human Drugs (2020)
- Acceptable Intake (AI) Limits: NDMA ≤ 96 ng/day
- Mandatory risk assessment, confirmatory testing, and control strategies (FDA, 2020)
See nitrosamine impurity testing methods aligned with FDA/ICH
2. Health Canada Regulations
Health Canada aligns closely with FDA guidance:
- Requires Risk Assessment Plans for all human drugs
- Mandates validated methods (LC-MS/MS, GC-MS, HRMS) for confirmatory testing
Explore our nitrosamine testing solutions for Health Canada compliance
Step-by-Step Guide to Compliance
Step 1: Perform a Nitrosamine Risk Assessment
A structured risk assessment identifies the potential for nitrosamine formation during drug manufacturing. Factors to consider:
- Active pharmaceutical ingredient (API) structure
- Synthetic process
- Excipients used
- Packaging components
- Storage conditions
Tip: Use decision trees provided in regulatory guidelines for comprehensive analysis (FDA, 2020).
Step 2: Conduct Confirmatory Testing
If a potential risk is found, testing is mandatory. Common techniques:
- LC-MS/MS – sensitive for NDMA, NDEA, NMBA
- GC-MS – ideal for volatile nitrosamines
- HRMS – for unknown or unexpected nitrosamines
Learn more about confirmatory analysis at ResolveMass
.
Step 3: Establish Acceptable Intake Limits
Guided by ICH M7 and Health Canada/FDA thresholds:
- NDMA: 96 ng/day
- NDEA: 26.5 ng/day
- Adjust based on population risk and therapeutic exposure
Step 4: Implement Control Strategies
Examples of mitigation:
- Modify API synthesis route
- Replace nitrosating reagents
- Tighten excipient specifications
- Add scavengers or change packaging materials
Step 5: Ongoing Monitoring and Documentation
Post-marketing surveillance is critical for continued compliance. Manufacturers should:
- Re-evaluate risks annually
- Monitor adverse events
- Maintain robust documentation and SOPs
ResolveMass supports long-term monitoring through analytical stability studies and real-time QC protocols.
Advanced Analytical Techniques for Nitrosamine Testing
Modern instruments allow low ppb (parts per billion) detection levels. Key tools include:
1. LC-MS/MS
Highly sensitive for detecting trace levels of NDMA, NDEA, and related compounds.
2. GC-MS
Effective for volatile nitrosamines with rapid turnaround time.
3. High-Resolution Mass Spectrometry (HRMS)
✔ Ideal for untargeted screening and novel impurity discovery
Explore our high-sensitivity testing capabilities
The Role of Contract Labs in Compliance
Outsourcing to specialized labs like ResolveMass Laboratories Inc. can accelerate compliance by providing:
- Method development and validation
- Matrix-specific calibration
- Regulatory-ready documentation
- Consultation and submission support
Challenges in Nitrosamine Analysis for OTC Products
Complex formulations (e.g., syrups, chewables)
Low concentrations (ppb–ppt)
Matrix interference
Batch variability
ResolveMass addresses these with:
- Custom sample prep
- Method validation per matrix
- Comprehensive QC protocols
AI-enhanced workflows help speed up testing and decision-making
Conclusion
With rising scrutiny on pharmaceutical impurities, nitrosamine testing for OTC products is no longer optional—it’s a regulatory necessity. Drug manufacturers operating in Canada and the U.S. must implement a structured, science-driven, and compliant approach to testing, risk management, and quality control.
ResolveMass Laboratories Inc. is a proven partner in this space, providing:
- Full-service analytical testing
- Expert regulatory guidance
- Compliance-ready documentation
- Rapid and reliable results
Reach out to start your compliance journey
Book a consultation with our team
REFERENCES
- Eissa ME. PHARMA’S NITROSAMINE CHALLENGE: A REVIEW OF A CALL FOR VIGILANCE. Universal Journal of Pharmaceutical Research. 2024 Jul 15.
- Seervi P. Regulatory Submission for Anda Dossier Filing and Current Impact of Gdufa Act (Doctoral dissertation, Institute of Pharmacy, Nirma University, A’bad).
- Slade J, Henningfield JE. Tobacco product regulation: context and issues. Food & Drug LJ. 1998;53:43.
- Pierrard-Meillon D. The Regulation of Cosmetic Products. InThe Science of Hair Care 1986 Apr 15 (pp. 501-540). CRC Press.
Ranitidine, nizatidine, and some antihypertensives have been under scrutiny.
LC-MS/MS and GC-MS are most commonly recommended.
Yes. FDA provides intake limits—e.g., NDMA: 96 ng/day.
Yes, but they must be validated per FDA and ICH standards.
Polymer Composition and Structure Analysis
Introduction Polymer Composition Analysis is the foundation for understanding how polymers behave in different industries,…
What Is Extractables and Leachables (E&L) Testing in Infusion Bags? A Complete Guide
Introduction Extractables and Leachables (E&L) Testing in Infusion Bags is one of the most important…
FDA Issues Guidance on Nitrosamine Leachables in Infusion Bags: Risks, Root Causes, and Testing Requirements
Introduction The U.S. Food and Drug Administration (FDA) has recently released new guidance on the…
Polymer Characterization Techniques Explained
Introduction Polymer Characterization Techniques Explained is a guide to the scientific methods used for studying…
Polymer Analysis Techniques & Methods
Introduction Polymer Analysis Techniques are essential for studying the structure, properties, and long-term reliability of…
Case Study: Size Exclusion Chromatography / GPC Analysis of Poly DADMAC Polymers
Introduction Size Exclusion Chromatography (SEC), also known as Gel Permeation Chromatography (GPC), is considered one…
